Eric Bartee

2.5k total citations
49 papers, 2.0k citations indexed

About

Eric Bartee is a scholar working on Genetics, Immunology and Oncology. According to data from OpenAlex, Eric Bartee has authored 49 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Genetics, 24 papers in Immunology and 19 papers in Oncology. Recurrent topics in Eric Bartee's work include Virus-based gene therapy research (29 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (13 papers). Eric Bartee is often cited by papers focused on Virus-based gene therapy research (29 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (13 papers). Eric Bartee collaborates with scholars based in United States, Canada and France. Eric Bartee's co-authors include Klaus Früh, Grant McFadden, Mandana Mansouri, Kristine Gouveia, Mohamed R. Mohamed, Ashley L. McCormack, Mee Y. Bartee, Masmudur M. Rahman, John W. Barrett and Christopher R. Cogle and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature reviews. Immunology and PLoS ONE.

In The Last Decade

Eric Bartee

45 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Bartee United States 22 785 774 623 616 555 49 2.0k
Angus C. Wilson United States 34 702 0.9× 1.4k 1.7× 532 0.9× 689 1.1× 1.5k 2.8× 67 3.0k
Jaquelin P. Dudley United States 28 1.1k 1.5× 1.1k 1.5× 777 1.2× 448 0.7× 383 0.7× 77 2.5k
Steven J. Werden United States 19 345 0.4× 813 1.1× 478 0.8× 574 0.9× 326 0.6× 23 1.6k
Chris Boutell United Kingdom 32 1.3k 1.6× 2.0k 2.6× 678 1.1× 809 1.3× 1.7k 3.1× 49 3.6k
Caroline E. Lilley United States 20 450 0.6× 1.1k 1.5× 674 1.1× 471 0.8× 909 1.6× 23 2.2k
Caroline A. Ray United States 13 553 0.7× 902 1.2× 476 0.8× 159 0.3× 667 1.2× 18 1.9k
Hans-Gerhard Burgert Germany 30 1.2k 1.6× 1.0k 1.3× 1.3k 2.1× 542 0.9× 830 1.5× 49 2.7k
Laurent Coscoy United States 25 1.1k 1.4× 1.2k 1.6× 275 0.4× 1.0k 1.7× 1.1k 2.1× 41 3.1k
Beihua Dong United States 24 1.4k 1.8× 1.6k 2.1× 322 0.5× 359 0.6× 398 0.7× 43 2.9k
Thomas M. Kristie United States 33 1.1k 1.4× 1.5k 1.9× 1.1k 1.8× 365 0.6× 2.1k 3.8× 56 3.6k

Countries citing papers authored by Eric Bartee

Since Specialization
Citations

This map shows the geographic impact of Eric Bartee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Bartee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Bartee more than expected).

Fields of papers citing papers by Eric Bartee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Bartee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Bartee. The network helps show where Eric Bartee may publish in the future.

Co-authorship network of co-authors of Eric Bartee

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Bartee. A scholar is included among the top collaborators of Eric Bartee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Bartee. Eric Bartee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bailey, Stefanie R., Eric Bartee, Kyle G. Daniels, et al.. (2025). Constructing the cure: engineering the next wave of antibody and cellular immune therapies. Journal for ImmunoTherapy of Cancer. 13(8). e011761–e011761.
2.
Bartee, Mee Y., et al.. (2024). IL-12-mediated toxicity from localized oncolytic virotherapy can be reduced using systemic TNF blockade. SHILAP Revista de lepidopterología. 32(3). 200866–200866.
3.
Heath, Blake R., Wang Gong, Kohei Okuyama, et al.. (2023). Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. Cell Reports. 42(4). 112303–112303. 19 indexed citations
4.
Bartee, Mee Y., et al.. (2023). Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus. Journal for ImmunoTherapy of Cancer. 11(6). e006388–e006388. 5 indexed citations
5.
Thomas, Raquela J., et al.. (2023). Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection. Molecular Therapy — Oncolytics. 30. 316–319. 4 indexed citations
6.
Taylor, Erik N., Colin M. Wilson, Yirong Yang, et al.. (2022). Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer. International Journal of Molecular Sciences. 23(18). 10525–10525. 4 indexed citations
7.
Bartee, Mee Y., et al.. (2022). TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. Journal for ImmunoTherapy of Cancer. 10(5). e004770–e004770. 9 indexed citations
8.
Smith, Aubrey S., Hannah M. Knochelmann, Megan M. Wyatt, et al.. (2022). B cells imprint adoptively transferred CD8 + T cells with enhanced tumor immunity. Journal for ImmunoTherapy of Cancer. 10(1). e003078–e003078. 12 indexed citations
9.
Thomas, Raquela J. & Eric Bartee. (2022). The use of oncolytic virotherapy in the neoadjuvant setting. Journal for ImmunoTherapy of Cancer. 10(4). e004462–e004462. 16 indexed citations
10.
Bartee, Mee Y., et al.. (2020). Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxviruses. PLoS ONE. 15(4). e0231977–e0231977. 4 indexed citations
11.
Aksoy, Bülent Arman, et al.. (2020). Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication. Journal for ImmunoTherapy of Cancer. 8(1). e000804–e000804. 8 indexed citations
12.
Bartee, Mee Y., et al.. (2019). Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. Journal for ImmunoTherapy of Cancer. 7(1). 11–11. 4 indexed citations
13.
Bartee, Eric, et al.. (2019). Syncytia Formation in Oncolytic Virotherapy. Molecular Therapy — Oncolytics. 15. 131–139. 30 indexed citations
14.
Bartee, Eric. (2018). Potential of oncolytic viruses in the treatment of multiple myeloma. PubMed. Volume 7. 1–12. 10 indexed citations
15.
Bartee, Mee Y., et al.. (2017). Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Research. 77(11). 2952–2963. 91 indexed citations
16.
Bartee, Eric, Amy Meacham, Elizabeth Wise, Christopher R. Cogle, & Grant McFadden. (2012). Virotherapy Using Myxoma Virus Prevents Lethal Graft-versus-Host Disease following Xeno-Transplantation with Primary Human Hematopoietic Stem Cells. PLoS ONE. 7(8). e43298–e43298. 14 indexed citations
17.
18.
Thibodeau, Jacques, Marie‐Claude Bourgeois‐Daigneault, Jessy Tremblay, et al.. (2008). Interleukin‐10‐induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. European Journal of Immunology. 38(5). 1225–1230. 138 indexed citations
19.
Bartee, Eric, et al.. (2004). Downregulation of Major Histocompatibility Complex Class I by Human Ubiquitin Ligases Related to Viral Immune Evasion Proteins. Journal of Virology. 78(3). 1109–1120. 271 indexed citations
20.
Früh, Klaus, Eric Bartee, Kristine Gouveia, & Mandana Mansouri. (2002). Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Research. 88(1-2). 55–69. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angus C. Wilson Breakdown of academic impact, for papers by Jaquelin P. Dudley Breakdown of academic impact, for papers by Steven J. Werden Breakdown of academic impact, for papers by Chris Boutell Breakdown of academic impact, for papers by Caroline E. Lilley Breakdown of academic impact, for papers by Caroline A. Ray Breakdown of academic impact, for papers by Hans-Gerhard Burgert Breakdown of academic impact, for papers by Laurent Coscoy Breakdown of academic impact, for papers by Beihua Dong Breakdown of academic impact, for papers by Thomas M. Kristie
Rankless by CCL
2026